Trial Profile
A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer. An IKZ-based phase II feasibility study.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 May 2010
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms DoCCS
- 10 May 2010 New trial record